Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries

Medicine and Dentistry

• Stent 100%
• Imatinib 36%
• Nanoparticle 36%
• Neointima 22%
• Coronary Artery 13%
• Cells 9%
• Vascular Smooth Muscle Cell 9%
• Platelet Derived Growth Factor Receptor 9%
• Drug-Eluting Stent 9%
• Phosphorylation 4%
• Serositis 4%
• Inpatient 4%
• Pathogenesis 4%
• Healing 4%
• In-Stent Restenosis 4%
• Obstetric Delivery 4%
• Adverse Event 4%
• Stenosis 4%
• thought 4%
• Mitogen-Activated Protein Kinase 4%
• Endothelial Cell 4%
• Intravascular Ultrasound 4%
• Restenosis 4%
• Thrombosis 4%
• Tyrosine-Kinase Inhibitor 4%
• Protein Tyrosine Kinase 4%
• Platelet Derived Growth Factor 4%
• Acute Coronary Syndrome 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Imatinib 36%
• Neointima 22%
• Pig 13%
• Platelet Derived Growth Factor Receptor 9%
• Healing 4%
• In-Stent Restenosis 4%
• Adverse Event 4%
• Pathogenesis 4%
• Mitogen Activated Protein Kinase 4%
• Protein Tyrosine Kinase 4%
• Platelet Derived Growth Factor 4%
• Protein Tyrosine Kinase Inhibitor 4%
• Stenosis 4%
• Restenosis 4%
• Thrombosis 4%
• Acute Coronary Syndrome 4%